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In February  the  World  Health  Organisation  (WHO)  recommends  inﬂuenza  viruses  to  be  included  in
inﬂuenza  vaccines  for the  forthcoming  winter  in  the  Northern  Hemisphere.  These  recommendations
are  based  on  data  collected  by  National  Inﬂuenza  Centres  (NICs)  through  the  WHO  Global  Inﬂuenza
Surveillance  and  Response  System  (GISRS)  and a more  detailed  analysis  of  representative  and  potential
antigenically  variant  inﬂuenza  viruses  from  the  WHO  Collaborating  Centres  for Inﬂuenza  (WHO  CCs)  and
Essential  Regulatory  Laboratories  (ERLs).  This  article  provides  a detailed  summary  of the  antigenic  and
genetic properties  of  viruses  and  additional  background  data  used  by WHO  experts  during  developmentaccine
uman
rivalent
of  the  recommendations  of  the  2013–2014  Northern  Hemisphere  inﬂuenza  vaccine  composition.
Published  by Elsevier  Ltd. This  is  an open  access  article  under  the  CC BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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. Introduction
In contrast to many other vaccines, inﬂuenza vaccines are fre-
uently updated to be effective against newly evolving human
nﬂuenza viruses that are likely to circulate in the following
nﬂuenza season. WHO  convenes technical consultations (vaccine
omposition meetings (VCM)) twice a year to provide guidance to
ational public health authorities and vaccine manufacturers on
he viruses to be included in trivalent or quadrivalent inﬂuenza
accines for the following inﬂuenza seasons in the Northern and
outhern Hemispheres. The committee assembled by WHO  com-
rises representatives from six WHO  CCs (Melbourne, Australia;
eijing, China; Tokyo, Japan; London, United Kingdom; Atlanta,
SA; Memphis, USA) and four ERLs (Therapeutic Goods Adminis-
ration (TGA), Australia; National Institute of Infectious Diseases
NIID), Japan; National Institute for Biological Standards and Con-
rol (NIBSC), UK; Food and Drug Administration (FDA), USA), with
bservers from H5 Reference Laboratories, WHO  NICs and other
xpert groups. The committee analyses data that encompass the
pidemiological, antigenic and genetic characteristics of the most
ecently circulating inﬂuenza viruses as well as preliminary vac-
ine effectiveness data where they are available. In addition, panels
f antisera from individuals (children, adults and elderly) who
eceived seasonal trivalent inactivated vaccines are tested to mea-
ure levels of antibodies to currently circulating inﬂuenza viruses.
he committee assesses which viruses are likely to predominate
n the forthcoming season and recommends vaccine candidates
ccordingly. With the WHO  recommendations in mind, national
nd international regulatory agencies should determine which
nﬂuenza viruses are best suited for inﬂuenza vaccines to be
icensed in their country.
In the present report we describe the basis for the selection
f candidate vaccine viruses recommended by the WHO  in the
013–2014 Northern Hemisphere inﬂuenza season. This report
escribes only those data that were available at the time of the
HO VCM held from February 18–20, 2013, in Geneva, Switzerland.
he recommended viruses in the 2013–2014 Northern Hemisphere
nﬂuenza season were:
 an A/California/7/2009 (H1N1)pdm09-like virus.
 an A/Victoria/361/2011 (A(H3N2)-like virus*.
 a B/Massachusetts/2/2012-like virus (Yamagata lineage).
here * indicates antigenically like the cell-propagated prototype
irus A/Victoria/361/2011. And for quadrivalent vaccines contain-
ng two B inﬂuenza viruses, the addition of:
 a B/Brisbane/60/2008-like virus (Victoria lineage).
. Inﬂuenza activity, September 2012–February 2013Inﬂuenza activity between the previous WHO  VCM for seasonal
nﬂuenza in September 2012 [1] and the VCM in February 2013
as reported by NICs and collated in the WHO  FluNet database
see http://www.who.int/ﬂunet). During this period, inﬂuenza
able 1
ow reacting inﬂuenza virus isolates as determined by haemagglutination inhibition assa
A(H1N1)pdm09b
Total tested 392 
Low  reactorsa (% of total) 13 (3.3%) 
a 8-fold lower or greater to homologous titre against the viruses listed below:
b Compared to A/California/7/2009 egg propagated virus.
c Compared to A/Victoria/361/2011 cell propagated virus.
d Compared to B/Brisbane/60/2008 egg propagated virus.
e Compared to B/Wisconsin/01/2010 or B/Hubei/Wujiangang/158/2009 egg propagated (2014) 4713–4725
activity was  reported worldwide. Inﬂuenza activity in countries in
the Northern Hemisphere was low in September and October but
increased activity was reported in North America in November, in
Europe from December onwards and in a number of countries in
Asia in December or January. In the Southern Hemisphere, inﬂuenza
activity generally declined from September onwards while in trop-
ical areas many countries reported outbreaks of varying intensity.
Regional A(H1N1)pdm09 activity was  reported by a few
countries in Asia, Central and South America as well as central
Africa. In January, many countries in northern, eastern and central
Europe and northern Africa (Algeria) had regional and widespread
outbreaks. Localised and sporadic activity was  also reported in
many other countries in northern Africa, Asia and North America.
Inﬂuenza A(H3N2) virus activity increased in November and
caused widespread outbreaks in Canada and the United States of
America where it was the predominant circulating virus subtype.
In Asia, regional outbreaks occurred in Cambodia from September
to November. Regional and widespread outbreaks were reported in
the Republic of Korea and Japan in January. Low-level activity was
reported in Europe from September to November but increased
during December and January in many countries. In northern
Africa, activity increased in January with widespread outbreaks
reported in Algeria. Sporadic and localised A(H3N2) activity was
also reported in Oceania, central (Cameroon) and southern Africa
and a number of countries in South America.
Inﬂuenza B virus activity increased in North America from
November with regional outbreaks reported by Mexico and the
United States of America and was predominant in Mexico. In
Europe, widespread outbreaks were reported in many countries in
January. In Asia activity was generally low. Localised and sporadic
B activity was  also reported by a number of countries in Africa,
Oceania and South America.
Inﬂuenza activity maps (maximum level of activity shown) for
the period August 2012–January 2013 along with graphs showing
the number of inﬂuenza viruses detected, typed and subtyped by
the GISRS laboratories from 2010 to 2013 are presented in Fig. 1.
At the time of the VCM, data collected from the GISRS labora-
tory network showed that, of the inﬂuenza viruses collected from
September 2012 to February 2013, approximately 92,298 (77%)
were type A and 27,695 (23%) type B; of the type A viruses 14,306
(15.5%) were A(H1N1)pdm09, 47,213 (51.2%) were A(H3N2) and
30,779 (33.3%) were not subtyped.
3. Overview of antigenic and genetic characteristics of the
viruses
For the Consultation, WHO  CCs performed detailed antigenic
analyses on 3147 inﬂuenza viruses (Table 1). Viruses were collected
from September 2012 to the beginning of February 2013 and recov-
ered from either clinical specimens or virus isolates provided by
NICs and other laboratories within and outside GISRS. Antigenic
characterisation was carried out predominantly by haemaggluti-
nation inhibition (HI) assays using viruses isolated and propagated
in either mammalian tissue culture cells (most frequently Madin-
Darby canine kidney cells (MDCK) or MDCK-SIAT-1 cells, the latter
ys at the WHO  CCs.
A(H3N2)c B/Victoriad B/Yamagatae
1923 435 397
13 (0.7%) 49 (11.2%) 41 (10.3%)
 viruses.
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tig. 1. Inﬂuenza activity August 2012–January 2013. Maps showing peak levels o
(H1N1)pdm09 viruses, (b) A(H3N2) viruses, (c) B viruses. The total number of sea
d)  A(H1N1)pdm09, (e) A(H3N2), (f) B viruses.
ngineered to express increased levels of -2,6 sialyl transferase
2]) or in embryonated hens’ eggs. HI assays using turkey or guinea
ig red blood cells (RBC) were performed to compare the reactiv-
ty of cultured viruses with post-infection ferret antisera raised
gainst egg- or cell-propagated reference viruses [3]. A subset of
iruses also underwent genetic characterisation. Genetic analyses
ere focused on the sequencing of the haemagglutinin (HA) and
euraminidase (NA) genes, with matrix (M)  gene or full genome
equencing performed on a smaller subset of viruses. HA gene
equencing supports HI assay results by providing the molecular
asis for any observed antigenic variation in circulating inﬂuenza
iruses, compared to current vaccine viruses, and phylogenetic
nalysis of HA and NA genes deﬁnes the genetic relatedness of cir-
ulating viruses within their particular A-subtype or B-lineage. The
nitial phylogenetic tree of the HA1 domain nucleotide sequences of
ach A-subtype or B-lineage was constructed with the PhyML soft-
are package version 3.0 [4] using GTR + I + 4. For this analysis
he general time-reversible model with the proportion of invariantratory conﬁrmed inﬂuenza (reported to FluNet) in each country with an NIC: (a)
nd pandemic viruses detected by GISRS for each type/subtype is shown in panels:
sites and the gamma  distribution of among-site rate variation with
four categories was  estimated from the empirical data, determined
by ModelTest [5] as the evolutionary model. GARLI v0.961 [6] was
run on the best tree from PhyML for 2 million generations to opti-
mise tree topology and branch lengths for each virus A-subtype or
B-lineage. The virus gene sequence accession numbers and their
originating laboratories used in this report are listed in Table S1.
A combination of antigenic and genetic data is routinely used
to identify emergent antigenic variants. Antigenic cartography [7]
was used to visualise the HI data. As discussed previously, the
behaviour of A(H3N2) viruses in HA and HI assays has changed
in recent years and their antigenic analyses have become more
complex [8]. In particular, guinea pig RBC are now preferred for
antigenic characterisation of current A(H3N2) viruses in HA and
HI assays. To control for the possible participation of the virus NA
in the agglutination of RBC, HI assays can also be performed in
the presence of oseltamivir [9]. Virus neutralisation (plaque reduc-
tion and microneutralisation) assays were performed in addition
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o HI tests for a subset of A(H3N2) viruses and a small number of
(H1N1)pdm09 viruses.
In addition to antigenic studies using post-infection ferret anti-
era, human serum panels obtained pre- and post-vaccination with
easonal inﬂuenza vaccine formulations were used to assess cur-
ent vaccine coverage against representative recently circulating
iruses. Serum panels for adults, elderly and paediatric populations
eceived from Australia, China, Japan, the UK and the USA were
ested where available.
. A(H1N1)pdm09 virusesOnly a relatively small number of A(H1N1)pdm09 viruses (392)
ere subjected to HI analysis by the WHO  CCs from September 2012
o February 2013. The majority of these viruses remained antigeni-
ally closely related to the vaccine virus A/California/7/2009 based
A/Swine/Ind
A/CALIFORNIA
A/California/4/09
A/Newcastle/18
A/India/57
A/
A/
A/Tun
A/
A/Indi
A/
A/Kenya
A/Mis
A/C
A/
A/
A/
A/Mex
A/Pue
A/Puerto
A/H
A/
October 2012
November 2012
December 2012
January 2013
A/H1N1
ig. 2. Phylogenetic comparison of inﬂuenza A(H1N1)pdm09 HA genes. A phylogenetic tre
onstructed with the PhyML software package 3.0 [4] using GTR + I + 4 as determined by
enerations to optimise tree topology and branch lengths. Viruses are colour-coded by m
ecember 2012 in purple and January 2013 in red. The current vaccine virus is shown in  (2014) 4713–4725
on assays with post-infection ferret antisera and only 3.3% of these
viruses had reduced titres of 8-fold or greater compared to titres
against the homologous virus (Table 1).
A high resolution phylogenetic tree of the HA genes was
constructed and included 379 A(H1N1)pdm09 isolates collected
through GISRS since February 2012 as shown in Fig. S1. While the
phylogenetic tree of the A(H1N1)pdm09 HA gene can be divided
into eight major genetic groups, the majority of viruses analysed
for the VCM belonged to group 6 with the signature amino acid
(AA) substitutions D97N, S185T and S451N in HA1 (Fig. 2, Fig.
S1). Fewer viruses belonged to group 7 (signature AA substitut-
ions N97D and A197T in HA1) were still present but fewer in
number than in the previous reporting period. Viruses from the
other groups were rare with the exception of a small number of
viruses from Japan, Norway and Africa which belonged to subgroup
8 (Fig. S1) and a group of viruses that appeared to be circulating
iana/P12439/00
A/Dakar/20/12-2012-12-09
/7/09
A/Norway/2552/12-2012-12-17
A/Saitama/88/12-2012-11-06
A/Brazil/229/2012-2012-05-20
A/Minnesota/06/2012-2012-03-20
2/11-2011-08-09
56/2011-2011-10-20
New-York/01/2013-2013-01-07
Ukraine/11/13-2013-01-08
A/Shanghai-Huangpu/SWL11324/2012-2012-12
isia/159/13-2013-01-04
A/Norway/108/13-2013-01-03
Limoges/26/13-2013-01-03
A/Gansu-Ganzhou/35/12-2012-11-19
a/1214/2012-2012-10-05
Sachsen/1/13-2013-01-03
A/Texas/99/2012-2012-12-17
/3294/2011-2011-07-19
iones/6563/12-2012-08-07
orrientes/66335/12-2012-08-03
Tucuman/A480/12-2012-08-31
A/Paraguay/20199/2012-2012-06-25
A/Ukraine/523/12-2012-12-02
A/Shimane/71/12-2012-11-20
A/Ningxia-Shapotou/SWL1297/2012-2012-12
A/Wisconsin/36/2012-2012-10-15
A/Beijing-Huairou/SWL11293/2012-2012-12
A/Beijing/SWLChaoyang-P031/2013-2013-01
Auckland/64/12-2012-08-01
Christchurch/11/12-2012-06-24
A/Brisbane/153/12-2012-07-16
ico/3723/2011-2011-12-12
rto-Rico/43/2012-2012-07-03
A/Peru/380/2012-2012-06-12
A/Peru/2023/2012-2012-10-26
A/Peru/0505/2012-2012-10-12
A/South-Carolina/19/2012-2012-10-22
A/Wisconsin/14/2012-2012-05-24
-Rico/09/2011-2011-07-19
eilongjiang-Xiangfang/SWL191/2011-2011-01
Stockholm/18/12-2012-02-27
A/Tanzania/2074/2012-2012-12-05
A/Yokohama/1/13-2013-01-07
A/Massachusetts/02/2013-2013-01-02
A/Belgium/G860/12-2012-11-08
A/India/7710/2012-2012-07-11
A/Bangladesh/5005/2012-2012-10-11
A/Stockholm/34/12-2012-11-06
7
6
5
8
e of representative A(H1N1)pdm09 HA1 coding-domain nucleotide sequences was
 ModelTest [5]. GARLI v0.961 [6] was run on the best tree from PhyML for 2 million
onth of collection as follows: October 2012 in green, November 2012 in orange,
capital letters. Genetic groups are labelled 5–8.
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Table  2
HI of A(H1N1)pdm09 viruses performed by CNIC.
Collection date y/m/d Reference ferret antisera HA gp Passage history
SCH/1 CA/7 HN/1432 TX/77 CA/18 HLJ/191
Reference viruses
A/Sichuan/SWL1/2009 2560 2560 640 640 640 2560 E4
A/California/7/2009 640 320 640 640 640 1280 E5
A/Hunan-Yueyanglou/SWL1432/2009 320 160 1280 640 640 640 E3
A/Texas/77/2009 320 320 2560 640 640 640 E4
A/California/18/2009 2560 2560 2560 1280 1280 2560 E4
A/Heilongjiang-Xiangfang/SWL191/2011 2560 2560 640 640 320 2560 7 E2
Test  viruses
A/Ningxia-Shapotou/SWL1297/2012 2012-12-03 2560 2560 1280 1280 640 2560 6 E2
A/Beijing-Haidian/SWL1997/2012 2012-12-12 2560 2560 1280 1280 320 2560 C4
A/Beijing-Haidian/SWL11010/2012 2012-12-17 2560 2560 1280 1280 640 2560 C3
A/Tianjin-Hedong/SWL1298/2012 2012-12-24 2560 2560 640 640 320 2560 C3
A/Xinjiang-Tianshan/SWL11144/2012 2012-12-20 2560 2560 640 640 320 2560 C1
A/Xinjiang-Tianshan/SWL11145/2012 2012-12-20 2560 2560 640 1280 640 2560 C3
A/Shanghai-Huangpu/SWL11284/2012 2012-12-04 2560 2560 320 640 320 2560 C3
A/Shanghai-Huangpu/SWL11324/2012 2012-12-21 2560 2560 1280 640 640 2560 6 C1
A/Gansu-Qilihe/SWL1412/2012 2012-12-18 2560 2560 1280 1280 640 2560 C3
A/Shanxi-Beilin/SWL11076/2012 2012-12-10 2560 2560 640 640 320 2560 C2
A/Shanxi-Xincheng/SWL1473/2012 2012-12-19 2560 2560 640 640 320 2560 C1
A/Shanxi-Xincheng/SWL1503/2012 2012-12-24 2560 2560 640 640 320 2560 C1
A/Beijing-Huairou/SWL11393/2012 2012-12-27 2560 2560 640 640 320 2560 C3
A/Beijing-Huairou/SWL127/2013 2013-01-03 2560 2560 1280 1280 640 2560 C1
A/Beijing-Huairou/SWL135/2013 2013-01-06 2560 2560 1280 640 640 2560 C1
A/Tianjin-Baodi/SWL1387/2012 2012-12-08 640 640 80 160 80 640 C2
160 320 320 320 320 C4
40 160 80 80 160 7 C3
40 80 80 40 160 7 C1
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Fig. 3. Antigenic cartography of A(H3N2) HI data. The antigenic map was gen-
erated using A(H3N2) HI data from the WHO  CC in Atlanta for viruses collected
between September 2011 and February 2013. Viruses are represented as circles and
are  colour-coded according to their origin (dark blue – North America, light blue
–  South America, green – Europe, orange – Africa, purple – Middle East, maroon –
Russia, red – East/South-East Asia, pink – Oceania) with viruses from earlier con-
sultations shown in grey. The egg-propagated vaccine virus A/Victoria/361/2011 is
shown as a large orange dot and the cell-propagated A/Victoria/361/2011 is shown
as  a large blue dot shows. The reference virus A/Texas/50/2012 is shown as a large
red dot (cell-propagated) and a large green dot (egg-propagated). Antisera are indi-A/Jilin-Chaoyang/SWL1640/2012 2012-11-28 80 
A/Beijing-huairou/SWL11293/2012 2012-12-07 80 
A/Beijing/SWLChaoyang-P031/2013 2013-01-07 40 
xclusively in West Africa, as represented by A/Dakar/20/2012
Fig. 2). AA substitutions in the 153–157 region of HA1 were
dentiﬁed in a number of cell- or egg-propagated A(H1N1)pdm09
iruses that had low reactivity to ferret antisera raised against
/California/7/2009 and some viruses had nucleotide polymor-
hism in their HA sequences encoding these amino acids (for
xample A/Beijing-Huairou/SWL11293/2013, Table 2). Generally,
hese 153–157 substitutions/polymorphisms were not detected in
he original clinical samples, indicating that they had arisen or
ecome predominant during adaptation to culture. Sequences of
solates with substitutions at positions 153–157 in the HA were
istributed throughout the phylogenetic tree and have appeared in
early all genetic groups in the past (data not shown). Full genome
equencing was carried out on viruses from several geographic
egions and no evidence of reassortment with co-circulating
(H3N2) viruses or other viruses was obtained (data not shown).
Antigenic cartography illustrated that the majority of
(H1N1)pdm09 isolates continued to be antigenically similar
o A/California/7/2009 and clustered together, demonstrating little
ntigenic diversity during this period or since 2009 (Fig. S2). In
ontrast many of the viruses with AA substitutions in the 153–157
egion of HA1 clustered together at some antigenic distance
rom the vaccine virus A/California/7/2009 and most other recent
solates (Fig. S2, Table 2).
Vaccines containing the A/California/7/2009 (H1N1pdm09)
ntigen stimulated anti-HA antibodies of similar geometric mean
I titres to the vaccine virus and the majority of representa-
ive A(H1N1)pdm09 isolates tested. Fig. S3 summarises human
erology following seasonal inﬂuenza vaccination. Only a few
(H1N1)pdm09 viruses showed a signiﬁcant (>50%) reduction in
eometric mean titres (GMT) in HI tests with human sera from
accinees who  received vaccines containing A/California/7/2009.
n some panels reductions were seen against egg-derived
/Bangladesh/2021/2012 virus which has an N156S substitu-
ion in HA1, a change known to alter the antigenic properties
f H1N1pdm09 viruses, as described above. Although reactivity
as also reduced against some cell-propagated viruses, such as
cated as squares and the grid indicates a 2-fold dilution in HI titre, 1 unit of antigenic
distance [7].
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Table 3
HI of A(H3N2) viruses performed by CDC.
Collection date y/m/d Reference ferret antisera HA gp Passage history
VIC/361 VIC/361 TX/50 TX/50 HI/22 HI/22 OH/2 OH/2 MT/5 PR/36
Reference viruses
A/Victoria/361/2011 2011-10-24 640 640 320 320 640 160 80 80 320 320 3C E3/E3
A/Victoria/361/2011 2011-10-24 80 160 160 320 320 160 160 160 160 320 3C C2/C3
A/Texas/50/2012 2012-04-15 640 1280 640 1280 1280 320 320 320 640 1280 3C E5
A/Texas/50/2012 2012-04-15 80 160 160 160 320 320 320 640 320 320 3C M1/C2
A/Hawaii/22/2012 2012-07-09 640 640 320 640 1280 1280 160 320 640 640 3C E4
A/Hawaii/22/2012 2012-07-09 40 80 160 160 320 320 160 160 160 320 3C C3
A/Ohio/02/2012 2012-03-08 80 320 40 320 160 160 320 320 320 320 3B E4/E2
A/Ohio/02/2012 2012-03-08 40 160 160 160 160 160 320 320 160 320 3B M1/C3
A/Montana/05/2011 2011-03-02 80 320 80 160 160 160 80 80 640 640 5 E3
A/Puerto  Rico/36/2012 2012-06-27 80 320 80 320 320 160 160 160 640 1280 6 E4
Test  viruses
A/South Dakota/15/2012 2012-10-30 640 640 320 640 1280 320 160 320 640 640 3C NC2E3
A/Alabama/32/2012 2012-12-18 80 320 320 320 320 160 160 160 160 320 C1/C1
A/Delaware/23/2012 2012-12-19 80 320 160 320 320 160 160 320 160 320 5 C2
A/fForida/01/2013 2013-01-03 80 320 320 320 320 320 320 320 320 320 5 C2
A/Florida/68/2012 2012-06-24 40 320 80 160 160 160 80 80 640 640 6 NC2E3
A/Kentucky/20/2012 2012-12-26 80 320 320 320 320 160 160 160 160 160 M1/C1
A/North  Carolina/01/2013 2013-01-03 80 320 320 320 160 320 320 320 320 320 3C M1/C1
A/North  Dakota/09/2012 2012-12-04 160 320 320 320 320 160 160 320 320 320 M1/C2
A/Wyoming/33/2012 2012-12-19 160 320 160 320 320 320 320 320 640 640 C2
A/Florida/66/2012 2012-12-31 80 320 320 320 320 160 160 160 160 320 MX/C1
A/Kentucky/21/2012 2012-12-16 80 160 320 320 320 160 320 320 160 320 M1/C1
A/Alabama/35/2012 2012-12-18 80 160 160 160 160 80 80 80 160 160 5 C1/C1
A/California/49/2012 2012-12-18 80 160 160 320 320 320 160 160 160 320 3C C2
A/Colorado/25/2012 2012-12-18 80 160 160 160 160 160 80 160 160 160 C1
A/fForida/67/2012 2012-12-31 80 160 320 320 320 160 160 160 160 320 MX/C1
A/Nevada/35/2012 2012-12-31 80 160 160 160 160 320 320 320 160 320 C1
A/Texas/01/2013 2013-01-08 80 160 160 160 160 160 160 160 160 320 3C M1/C1
A/Uah/34/2012 2012-12-31 40 160 160 160 160 80 160 160 160 160 C2
A/Wyoming/01/2013 2013-01-03 80 160 160 160 160 160 160 160 160 320 3C C1
A/Illinois/21/2012 2012-12-10 40 160 160 160 160 80 80 80 80 80 C2
A/West  Virginia/01/2013 2013-01-03 40 80 160 160 160 80 160 160 80 80 3C C2
A/Beijing-Xicheng/12423/2012 2012-10-04 40 80 80 80 80 80 80 80 80 80 3C C3/C4
A/North  Dakota/08/2012 2012-12-06 40 40 80 80 80 80 80 80 80 80 3C M1/C1
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A/South-Australia/102/2001
A/Brisbane/10/07-2007-02-06
A/Perth/16/09
A/Montana/05/2011-2011-03-02
A/Stockholm/31/12-2012-10-17
A/Mecklenburg-Vorpommern/12/12-2012-12-27
A/Delaware/23/2012-2012-12-19
A/Alabama/35/2012-2012-12-18
A/New-York/40/2012-2012-10-16
A/Florida/01/2013-2013-01-03
A/Ukraine/78/12-2012-02-16
A/Ukraine/5398/12-2012-04-01
A/Puerto-Rico/36/2012-2012-06-27
A/Tennessee/10/2012-2012-11-01
A/Johannesburg/5223/12-2012-06-07
A/Victoria/893/12-2012-08-27
A/Alaska/22/2012-2012-10-01
A/Iwate/26/12-2012-02-04
A/Kagawa/22/12-2012-02-13
A/Belgrade/449/12-2012-02-02
A/Ohio/02/2012-2012-03-08
A/North-Carolina/01/2012-2012-01-19
A/Colorado/11/2012-2012-03-07
A/Netherlands/2/12-2012-01-12
A/Cairo/140/12-2012-12-27
A/Cairo/136/12-2012-12-27
A/American-Samoa/7102/2011-2011-08-31
A/VICTORIA/361/11
A/Nonthaburi/110/11-2011-07-06
A/Victoria/874/12-2012-08-17
A/Tasmania/12/12-2012-06-24
A/Brisbane/29/12-2012-03-31
A/Laos/SA085/11-2011-09-07
A/Mauritius/549/12-2012-06-22
A/Hubei-Wuhan-Jiangan/163/12-2012-02-13
A/Hawaii/22/12-2012-07-09
A/TEXAS/50/12-2012-04-15
A/Singapore/22/12-2012-06-06
A/Sachsen/2/13-2013-01-07
A/Texas/01/2013-2013-01-08
A/Fukuoka/2/12-2012-12-28
A/Beijing-Xicheng/12423/12-2012-10-04
A/Wyoming/01/2013-2013-01-03
A/Dakar/4/12-2012-10-03
A/Lisboa/SU15/12-2013-01-04
A/Virginia/03/2013-2013-01-04
A/Clermont-Ferrand/14/13-2012-12-23
A/Nordrhein-Westfalen/1/13-2013-01-03
A/England/676/12-2012-12-29
A/West-Virginia/01/2013-2013-01-03
A/North-Carolina/01/2013-2013-01-03
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nd  annotated as described for Fig. 2. Genetic subgroups are labelled 3A, 3B, 3C, 5 a
/Stockholm/34/2012, no reduction was seen in HI studies of this
irus using post-infection ferret antiserum.
Based on analyses of data presented at the VCM, it was  con-
luded that the observed genetic diversity of A(H1N1)pdm09
iruses had not resulted in changes in their antigenic properties
nd that A/California/7/2009, remained appropriate for use in the
013–2014 Northern Hemisphere vaccine.
. A(H3N2) virusesThe majority (61.1%) of seasonal inﬂuenza viruses analysed
y the WHO  CCs during the September 2012–February 2013
eriod were inﬂuenza A(H3N2) viruses (Table 1). The WHO
Cs used a variety of antigenic assays to analyse the 1923epresentative A(H3N2) HA1 coding-domain nucleotide sequences was constructed
A(H3N2) viruses collected and showed that the vast majority
of these viruses were antigenically similar to MDCK-propagated
A/Victoria/361/2011 A(H3N2) virus, with less than 1% being low
reacting (those with 8-fold or lower titres compared to the homol-
ogous titre; Table 1). However, ferret antisera raised against
the egg-propagated A/Victoria/361/2011 virus recognised recent
A(H3N2) MDCK virus isolates poorly with many viruses showing
8-fold or greater reduction in titres compared to the homologous
virus titre. Ferret antisera raised to another recent egg-propagated
virus (A/Texas/50/2012) that was genetically closely related to
A/Victoria/361/2011, recognised many recent MDCK-propagated
A(H3N2) viruses well. This is exempliﬁed in Table 3 which shows
that antiserum raised against A/Texas/50/2012 recognised the great
majority of test viruses with a titre within 4-fold of the titre to
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B/Malaysia/2506/2004
B/Hong-Kong/45/05-2005-02-07
B/Ohio/1/05-2005-02-23
B/Hong-Kong/90/2008-2008-02-04
B/Liaoning-Dandong-Zhenxing/1281/12-2012-11-12
B/Bangladesh/4008/08-2008-06-15
B/Kobe/166/11-2011-07-15
B/Sydney/508/2010-2010-10-11
B/Jiangsu-Zhenjiang-Runzhou/1697/12-2012-11-15
B/Laos/I772/12-2012-10-09
B/Sichuan-Maerkang/166/11-2011-07-14
B/Jiangxi-Jiujiang-Xunyang/52/12-2012-12-18
B/Montana/06/2012-2012-10-28
B/Jiangsu-Tianning/1666/12-2012-12-06
B/Nong-Khai/112/11-2011-07-04
B/Dakar/1/12-2012-04-12
B/Sydney/230/2012-2012-11-23
B/Mauritius/614/12-2012-07-11
B/Texas/20/2012-2012-11-12
B/South-Australia/11/12-2012-05-12
B/Darwin/40/12-2012-06-08
B/Nebraska/05/2012-2012-11-20
B/Okinawa/37/12-2012-11-28
B/Okinawa/38/12-2012-12-11
B/Kochi/112/12-2012-12-12
B/Kentucky/04/2012-2012-10-30
B/Jiangsu-Zhenjiang-Danyang/1718/12-2012-11-15
B/Jiangsu-Suzhou-Pingjiang/1494/12-2012-12-06
B/Poitiers/2821/12-2012-12-12
B/North-Dakota/01/2012-2012-11-07
B/Costa-Rica/9188/2012-2012-07-14
B/Egypt/3514/2012-2012-06-13
B/Iowa/03/2012-2012-11-07
B/England/595/12-2012-11-09
B/Bavaria/1/13-2013-01-03
B/Wisconsin/12/2012-2012-11-19
B/Wyoming/03/2012-2012-05-22
B/Florida/38/2012-2012-10-30
B/Sachsen/26/12-2012-12-18
B/Jordan/30014/12-2012-12-30
B/Singapore/41/2012-2012-11-16
B/Victoria/832/2012-2012-12-12
B/Victoria/835/2012-2012-12-26
B/Brisbane/140/12-2012-10-30
B/Burgos/95/12-2012-11-14
B/Valladolid/96/12-2012-12-26
B/Argentina/9410/2012-2012-08-26
B/BRISBANE/60/08
B/Nagano/3470/12-2012-11-28
B/Denmark/23/12-2012-11-05
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tig. 5. Phylogenetic comparison of inﬂuenza B (Victoria-lineage) HA genes. A phylog
as  constructed and annotated as described for Fig. 2. A single genetic group is lab
he homologous antigen. An HI assay performed in the presence
f 20 nM oseltamivir with guinea pig RBC (Table S2) and virus
laque-reduction (Tables S3 and S4) or microneutralisation (Table
5) assays showed similar results.
Antigenic cartography showed that recently circulating
ell-propagated A(H3N2) viruses clustered around both the
/Victoria/361/2011 and the A/Texas/50/2012 MDCK-propagated
iruses with the equivalent egg-propagated viruses being placed
ome distance away (Fig. 3). It was concluded that while the
ajority of A(H3N2) viruses that circulated from September
012 to February 2013 were antigenically related to the
/Victoria/361/2011 MDCK-propagated virus, they were bet-
er inhibited or neutralised by ferret antisera raised against tree of representative B/Victoria lineage HA1 coding-domain nucleotide sequences
.
egg-propagated A/Texas/50/2012 than by those raised against
egg-propagated A/Victoria/361/2011.
A simple phylogenetic tree for the HA of A(H3N2) viruses is pre-
sented in Fig. 4 and a high resolution tree with HA sequences of
872 A(H3N2) viruses collected through GISRS since February 2012
is shown in Fig. S4.
The majority of circulating viruses belonged to genetic group
3 with the signature AA substitution V223I. The group 3 viruses
currently can be further divided into subgroups 3A, 3B and 3C.
Subgroup 3A viruses carry AA substitutions at N144D (leading
to the loss of a potential glycosylation site) and N145S in HA1.
Subgroups 3B and 3C isolates carry AA substitutions A198S and
N312S, while 3C viruses carry additional AA substitutions at S45N
ine 32 (2014) 4713–4725 4721
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Fig. 6. Antigenic cartography of inﬂuenza B (Yamagata-lineage) HI data. The anti-
genic map was  generated using B/Yamagata HI data from the WHO  CC in London for
viruses collected between September 2011 and January 2013. Colour coding is the
same as in Fig. 3 with the exception that B/Wisconsin/1/2010 (egg-propagated) isI.G. Barr et al. / Vacc
leading to the gain of a possible glycosylation site) and T48I
n HA1. Many subgroup 3C viruses also carry an additional AA
ubstitution at N145S along with a further substitution at T128A,
hich results in the loss of a glycosylation site, and R142G. Groups
 and 6 have signature AA substitutions D53N, Y94H, I230V and
280A in HA1, with group 6 isolates carrying an additional AA
ubstitution S199A. Most of the A(H3N2) viruses collected since
eptember 2012 fell into genetic subgroup 3C represented by
/Victoria/361/2011 with a small number, mainly from the US and
urope, belonging to subgroup 3A and group 5. Just a few viruses
ell into subgroup 3B and group 6 (Fig. 4, Fig. S4).
Some isolates from North America, Europe and Asia belonged
o groups 5 and 6, which have signature AA substitutions D53N,
94H, I230V and E280A in HA1, with group 6 isolates carrying
n additional AA substitution S199A. Viruses with low HI titres
o post-infection ferret antisera raised against cell-propagated
/Victoria/361/2011 viruses were scattered throughout the HA
ree and did not form monophyletic groups or share common
A substitutions. Genetic analysis of the HA sequences of several
gg-propagated A/Victoria/361/2011-like viruses were compared
n order to see if low HI titres might be associated with amino
cid substitutions linked to adaptation to growth in eggs. A num-
er of such substitutions were noted in the HA of the initial
gg-propagated A/Victoria/361/2011 wild-type virus, including a
156R substitution. A subsequent R156Q change was acquired in
he high growth reassortants IVR-165 and X221, although H156R
as retained in the reassortant NIB-79. Changes in amino acid
equence in this area of the HA of A(H1N1)pdm09 viruses have
een shown to alter their antigenic properties and, based on
he ferret and human serology obtained for the egg-propagated
/Victoria/361/2011 virus, such substitutions may  also have altered
he antigenicity of this virus. Some egg-propagated viruses geneti-
ally similar to A/Victoria/361/2011, such as A/Texas/50/2012, did
ot have similar adaptive substitutions in the 153–157 HA region.
gg-propagated A/Hawaii/22/2012 and the high growth reassor-
ants made from this virus, X225 and X225A, had the substitution
157S and in HI assays antisera raised against A/Hawaii/22/2012
ecognised the majority of test viruses with titres reduced more
han 4-fold compared to the homologous virus (Table 3).
Vaccines containing inﬂuenza A/Victoria/361/2011 (H3N2)-like
ntigen stimulated anti-HA antibodies in all age groups that had
educed geometric mean HI titres to the majority of cell-propagated
(H3N2) viruses compared to the egg-propagated vaccine virus or
ther egg-propagated recent viruses (Fig. S5). The average reduc-
ions in HI GMT  against cell-propagated A(H3N2) viruses compared
o the egg-propagated vaccine virus were 66% for adults, 68% for the
lderly and 64% for children.
Based on surveillance data available in February 2013, it
as concluded that the A(H3N2) component of the 2012–2013
orthern Hemisphere inﬂuenza vaccine should remain as a
/Victoria/361/2011-like virus. However it was stipulated that the
ike virus should be antigenically like the cell-propagated proto-
ype virus. For this reason a new vaccine virus A/Texas/50/2012
nd its reassortants, X-223 and X223A, were recommended for use
n vaccines that are based on egg propagation.
. Inﬂuenza B viruses
From September 2012 to February 2013, 832 inﬂuenza B viruses
ere analysed by WHO  CCs. Of these 435 were B/Victoria-lineage
iruses (52.3%) and 397 were B/Yamagata-lineage viruses (47.7%).
he analyses of inﬂuenza B viruses by HI assays continued to
emonstrate that antisera raised in ferrets infected with egg-grown
 viruses may  react poorly with cell-grown B viruses, prompting
he extensive use of cell-grown viruses for antiserum production
n ferrets for use in HI assays [8]. In addition, inﬂuenza B virusesshown as a large blue dot and B/Massachusetts/2/2012 (egg-propagated) is shown
as  a large red dot.
often generate antisera with lower titres than those raised against
inﬂuenza A viruses and some WHO  CCs undertake additional boost-
ing of ferrets, which can potentially broaden the cross-reactivity of
the antibody responses.
For the B/Victoria-lineage viruses collected from September
2012 to February 2013, the combined HI data from all WHO
CCs showed approximately 11% of isolates to have reduced
HI titres with post-infection ferret antiserum raised against
B/Brisbane/60/2008, a previously recommended vaccine virus of
the B/Victoria-lineage, or cell-propagated viruses genetically simi-
lar to it (Table 1). During this period few differences were seen in
HI reactivity (Table 4) or in antigenic maps created from these data
(Fig. S6).
The vast majority of HA genes from recent B/Victoria-lineage
viruses fell into genetic group 1 represented by B/Brisbane/60/2008
with signature AA substitutions N75K, N165K and S172P in HA1
(Fig. 5). A high resolution tree constructed with HA sequences
from 357 B/Victoria-lineage isolates collected through GISRS since
February 2012 is shown in Fig. S7 and illustrates the high pre-
dominance of recent viruses in genetic group 1. Genetic subgroups
within group 1, 1A and 1B, have been identiﬁed and are associ-
ated with the amino acid substitution L58P in HA1. The majority
of viruses were in subgroup 1A with leucine at residue 58 of
HA1. Some of the recent virus isolates, mainly from China, that
fell into subgroup 1B had proline at residue 58 of HA1 and had
NA genes from different groups of the B/Victoria lineage, namely
HA genes from the B/Victoria-lineage subgroup 1B and NA genes
from HA group 4 viruses (HA-1B/NA-4) with these intra-lineage
reassortant viruses having the additional AA substitutions K272Q,
E320K, D384N and A465T (the latter change leading to the gain
of a potential glycosylation site) in the NA compared with viruses
that carried both the HA and NA genes of genetic group 4. Viruses
in a third small cluster within subgroup 1A carried the HA1 AA
substitution V146I. An additional cluster within subgroup 1A has
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Table 4
HI of B Victoria-lineage viruses performed by VIDRL.
Collection date y/m/d Reference ferret antisera Passage history
MAL/2506 PHIL/6363 SING/616 CAMB/30 BRIS/60 BRIS/60 BRIS/33 HK/90 SYD/508 DAR/40
Reference viruses
B/Malaysia/2506/2004 640 1280 1280 1280 20 320 640 320 160 <20 E5
B/Philippines/6363/2009 320 1280 >2560 640 <20 80 160 160 80 <20 MDCK3
B/Singapore/616/2008 320 640 640 640 <20 160 160 160 80 20 MDCK5
B/Cambodia/30/2011 640 1280 1280 1280 20 320 320 160 160 40 E3
B/Brisbane/60/2008 40 80 40 40 320 160 320 320 160 640 MDCKX
B/Brisbane/60/2008 160 320 320 640 160 640 640 1280 640 320 E6
B/Brisbane/33/2008 160 320 320 640 160 640 640 640 640 320 E4
B/Hong  Kong/90/2008 320 640 640 640 160 640 640 1280 1280 320 E5
B/Sydney/508/2010 160 320 320 640 160 640 640 640 640 320 E3
B/Darwin/40/2012 20 160 40 80 640 160 320 320 160 640 MDCK2
Test  viruses
B/Sth Australia/73/2012 2012/11/30 320 640 320 320 320 640 640 640 640 320 E3
B/Sth  Australia/81/2012 2012/11/28 160 320 640 320 160 640 640 640 640 320 E4
B/Sth  Australia/77/2012 2012/11/30 40 160 40 80 640 160 320 320 320 640 MDCK2
B/Sydney/226/2012 2012/11/23 80 160 80 80 320 320 320 320 320 640 MDCKX
B/Victoria/1023/2012 2012/11/05 20 80 40 40 320 160 320 320 160 640 MDCK1
B/Victoria/1025/2012 2012/11/06 20 160 40 80 640 160 320 320 160 640 MDCK1
B/Victoria/1026/2012 2012/11/09 40 160 40 80 640 160 320 320 160 640 MDCK1
B/Victoria/835/2012 2012/12/26 20 80 40 80 640 160 320 320 160 640 MDCK1
B/Singapore/38/2012 2012/10/01 40 160 40 80 640 320 320 640 160 640 MDCK2
B/Singapore/39/2012 2012/10/13 20 160 80 80 640 160 320 320 160 1280 MDCK2
B/Singapore/40/2012 2012/11/19 20 160 40 80 80 160 320 320 160 640 MDCK2
B/Singapore/41/2012 2012/11/16 40 160 40 80 320 160 320 320 160 640 MDCK2
B/Sydney/217/2012 2012/11/12 20 80 40 40 160 80 320 320 160 320 MDCKX
B/Victoria/832/2012 2012/12/12 20 80 40 40 320 80 160 160 160 640 MDCK1
B/Sydney/219/2012 2012/11/08 <20 40 20 40 160 80 160 160 80 640 MDCKX
B/Sydney/228/2012 2012/11/26 <20 40 20 40 160 80 160 160 80 320 MDCKX
B/Sydney/229/2012 2012/11/26 20 80 20 40 320 80 160 160 160 640 MDCKX
B/Sydney/231/2012 2012/11/27 <20 40 20 40 160 80 160 160 80 320 MDCKX
B/Sydney/232/2012 2012/11/26 20 40 20 40 320 80 160 160 160 640 MDCKX
B/Sydney/230/2012 2012/11/23 <20 40 20 40 160 80 80 160 80 320 MDCKX
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Table 5
HI of B Yamagata-lineage viruses performed by NIMR.
Collection date y/m/d Reference ferret antisera HA gp Passage history
FLO/4 BRIS/3 WIS/1 STOC/12 EST/55669 SERB/1894 STO/12 MASS/O2 MASS/02
Reference viruses
B/Florida/4/2006 2006-12-15 1280 1280 640 1280 320 80 1280 1280 640 1 E3/E3
B/Brisbane/3/2007 2007-09-03 640 640 320 640 160 10 320 1280 160 2 E2/E1
B/Wisconsin/1/2010 2010-02-20 320 80 640 640 40 40 640 640 40 3 E3/E2
B/Stockholm/12/2011 2011-03-28 80 40 160 640 10 10 320 320 20 3 E4/E2
B/Estonia/55669/2011 2011-03-14 160 80 80 160 640 80 160 320 640 2 MDCK1/MDCK1
B/Serbia/1894/2011 2011-03-08 80 80 80 160 160 160 160 160 320 3 MDCK1/MDCK4
B/Stockholm/12/2011 2011-03-28 160 80 160 320 320 20 320 320 640 3 Cx/MDCK2
B/Novosibirsk/1/2012 2012-02-14 < 80 80 160 80 80 160 160 80 3 C2/MDCK2
B/Hong  Kong/3577/2012 2012-06-13 160 40 40 80 640 20 80 160 640 2 MDCK2/MDCK1
B/Massachusetts/02/2012 2012-03-13 320 160 160 320 80 20 320 640 40 2 E3/E2
B/Massachusetts/02/2012 2012-03-13 160 80 40 160 160 20 40 640 160 2 MDCK1/C2/MDCK2
Test  viruses
B/Paris/1443/2012 2012-04-16 80 40 160 320 40 80 320 320 80 MDCK2/MDCK1
B/Ghana/DILI-0409/2012 2012-08-02 80 40 160 320 80 80 320 160 160 SIAT1/MDCK1
B/Ghana/DILI-0309/2012 2012-07-18 40 40 80 320 40 80 160 160 80 SIAT2/MDCK1
B/Ghana/DILI-0369/2012 2012-07-25 40 40 80 320 80 80 160 160 80 SIAT2/MDCK1
B/Ghana/FS-968/2012 2012-07-27 40 20 80 320 80 80 320 320 80 SIAT2/MDCK1
B/Ghana/DILI-0396/2012 2012-08-02 80 40 80 320 80 80 320 320 80 3 SIAT1/MDCK1
B/Ghana/ARI 1648/2012 2012-08-30 80 40 80 160 80 80 160 160 80 3 SIAT3/MDCK1
B/Ghana/FS-1120/2012 2012-09-09 80 40 80 160 160 80 320 160 160 SIAT3/MDCK1
B/Paris/1466/2012 2012-09-24 160 80 80 160 640 40 160 320 160 MDCK2/MDCK1
B/Ghana/DILI-0859/2012 2012-10-19 80 40 80 320 40 80 320 320 80 3 SIAT2/MDCK1
B/Caen/1808/2012 2012-11-16 40 40 80 320 20 40 160 160 80 MDCK1/MDCK1
B/Pays  de Loire/1791/2012 2012-11-19 160 160 80 320 640 80 80 320 320 MDCK1/MDCK1
B/Hyogo/4002/2012 2012-12-11 80 40 80 160 40 40 160 320 80 3 MDCK2/MDCK1
B/Ukraine/2/2013 2013-01-07 320 80 80 320 640 40 80 320 320 MDCK2/MDCK1
B/Paris/1448/2012 2012-07-13 160 80 40 160 640 20 80 320 160 MDCK2/MDCK1
B/Ghana/DILI-0362/2012 2012-07-25 80 20 40 80 40 80 160 80 80 SIAT3/MDCK1
B/New  Mexico/04/2012 2012-11-26 160 80 40 160 640 40 40 320 160 2 MDCK1/C1/MDCK1
B/Yokohama/82/2012 2012-12-07 80 80 40 80 320 40 80 160 160 2 MDCK2/MDCK1
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B/Shanghai/361/2002
B/Florida/4/2006
B/Brisbane/3/2007
B/Perth/24/12-2012-02-28
B/Victoria/325/12-2012-09-02
B/Brisbane/54/12-2012-06-28
B/Brisbane/63/12-2012-07-24
B/Athens/199/12-2012-02-07
B/Lisboa/1/12-2012-02-28
B/Taiwan/928/11-2011-10-10
B/Iwate/5/12-2012-02-04
B/Vermont/01/2012-2012-02-07
B/New-Hampshire/03/2012-2012-02-24
B/Santiago/47508/12-2012-06-29
B/South-Australia/45/12-2012-10-03
B/Norway/2157/12-2012-11-04
B/Kawasaki/10/12-2012-02-06
B/Saitama/29/12-2012-03-02
B/Massachusetts/02/2012-C-2012-03-13
B/MASSACHUSETTS/2/12-E-2012-03-13
B/Sapporo/40/12-2012-03-01
B/Nevada/17/2012-2012-12-14
B/Hong-Kong/3577/12-2012-06-13
B/Denmark/26/12-2012-11-26
B/New-Mexico/04/2012-2012-11-26
B/Uruguay/12/2012-2012-07-19
B/Lyon/2771/12-2012-12-17
B/England/707/12-2012-12-29
B/Ohio/06/2012-2012-11-19
B/Thuringen/1/13-2013-01-07
B/Kentucky/05/2012-2012-11-21
B/Bangladesh/3333/2007
B/Ghana/ARI-1648/12-2012-08-30
B/Ghana/DILI-0859/12-2012-10-19
B/Ghana/DILI-0396/12-2012-08-02
B/Pennsylvania/02/2012-2012-03-01
B/Quebec/RV2958/12-2012-11-17
B/Hubei-Wujiagang/158/2009
B/Wisconsin/1/2010
B/Denmark/8/12-2012-02-29
B/New-Mexico/06/2011-2011-10-25
B/Taiwan/1088/12-2012-02-23
B/Chanthaburi/2460/12-2012-09-05
B/Norway/1995/12-2012-10-11
B/Hyogo/4002/12-2012-12-11
B/Bangladesh/9265/2012-2012-09-22
B/Hawaii/13/2012-2012-11-03
B/Wisconsin/02/2012-2012-02-04
B/Maryland/03/2012-2012-02-24
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oig. 7. Phylogenetic comparison of inﬂuenza B (Victoria-lineage) HA genes. A ph
equences was  constructed and annotated as described for Fig. 2. Genetic groups ar
ndergone intra-lineage reassortment inheriting the NA gene from
solates similar to those in HA group 3 (HA-1A/NA-3, represented
y B/Uruguay/12/2008), but with additional AA substitutions L73F,
397R, M375K and A389T in the NA and another intra-lineage reas-
orted group with V15I in the HA1. The latter circulated recently in
orth America, Japan and Europe (Fig. S7).
For the B/Yamagata-lineage viruses collected from September
012 to February 2013, the combined HI data from all WHO  CCs
howed that approximately 10% of the isolates had reduced HI titres
8-fold or greater compared to the homologous titre) with post-
nfection ferret antiserum raised against B/Wisconsin/1/2010, the
reviously recommended vaccine virus (Table 5). At some of the
Cs, certain recent viruses reacted with lower titres in HI assays
ith ferret antisera raised against either B/Wisconsin/1/2010
r B/Hubei-Wujiagang/158/2009 egg-propagated viruses. Thesenetic tree of representative B/Yamagata-lineage HA1 coding-domain nucleotide
lled 2 and 3.
differences were also observed in antigenic cartography of
B/Yamagata viruses (Fig. 6) in which two  groups of viruses were
apparent, one clustering around B/Wisconsin/1/2010 and the other
around B/Massachusetts/2/2012.
The majority of HA genes of recent B/Yamagata-
lineage viruses fell within genetic group 2 (represented by
B/Massachusetts/2/2012) with signature AA substitutions R48K,
P108A, T182A and S230G in HA1. Fewer belonged to group 3 (repre-
sented by B/Wisconsin/1/2010 and B/Hubei-Wujiagang/158/2009)
with signature AA substitutions S150I, N166Y and G230D (see
Fig. 7 and also Fig. S8 for a high resolution tree constructed with
sequences of 306 B/Yamagata lineage isolates collected by GISRS
since February 2012). Group 2 viruses predominated globally with
the exception of China where group 3 viruses were dominant
during this period (Fig. S8).
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sphere season. Vaccine 2010;28(Feb (5)):1156–67.
[9] Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, et al. Neuraminidase
receptor binding variants of human inﬂuenza A(H3N2) viruses resulting from
substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?
J  Virol 2010;84(July (13)):6769–81.I.G. Barr et al. / Vacc
Data generated by WHO  CCs and ERLs showed that the
ost-vaccination antisera obtained from people immunised with
accines containing B/Wisconsin/1/2010 or B/Hubei-Wujiagang/
58/2009-like viruses generally reacted well with recent inﬂuenza
 viruses from the B/Yamagata lineage, but less well with B viruses
rom the B/Victoria lineage (Fig. S9). Some serum panels gave sig-
iﬁcantly lower anti-HA antibody titres against genetic group 2
iruses than against genetic group 3 B/Yamagata-lineage viruses.
Based on the increasing proportion of B/Yamagata-lineage
iruses, notably those falling within HA genetic group 2, in many
arts of the world during the surveillance period and the antigenic
ifferences observed between group 2 and group 3 B/Yamagata-
ineage viruses, it was concluded that a B/Massachusetts/2/2012-
ike virus (group 2; B/Yamagata-lineage) would be the most
ppropriate virus for trivalent vaccine compositions for use in the
orthern Hemisphere for the 2013–2014 season. For quadrivalent
nﬂuenza vaccines containing two inﬂuenza B viruses, it was rec-
mmended that the additional B virus be a B/Brisbane/60/2008-like
irus of the B/Victoria lineage.
. Antiviral resistance
The two classes of antiviral drugs currently licensed for the
revention and treatment of inﬂuenza are the adamantanes or
2 ion channel blockers (amantadine and rimantadine) and the
euraminidase inhibitors (oseltamivir, zanamivir and, in some
ountries, peramvir and laninamivir). All A(H1N1)pdm09 viruses
creened for resistance markers carried the AA substitution S31N
n the M2  protein associated with resistance to amantadine
nd rimantadine. There were sporadic detections A(H1N1)pdm09
iruses with reduced or highly reduced inhibition by oseltamivir
ue to the H275Y substitution in NA which has been associated
ith clinical resistance to this drug. The prevalence of resis-
ance to oseltamivir remains low worldwide (1–2%, data not
hown) and the available data for this consultation did not indi-
ate a signiﬁcantly increased proportion of oseltamivir resistant
(H1N1)pdm09 viruses isolated from patients not exposed to
he drug compared to previous seasons (data not shown). All
(H1N1)pdm09 viruses were sensitive to zanamivir (data not
hown). All but one A(H3N2) virus characterised, A/Cairo/136/2012
ollected in December 2012 (S31), were resistant to adamantanes
based on the presence of the M2  protein AA substitution S31N)
ut all were sensitive to neuraminidase inhibitors oseltamivir and
anamivir (data not shown). Most inﬂuenza B viruses analysed
ere sensitive to oseltamivir and zanamivir: only one B isolate
ested showed reduced inhibition by oseltamivir (data not shown).cknowledgements
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